quinazolines has been researched along with carfilzomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boufraqech, M; Kebebew, E; Lake, R; Zhang, L | 1 |
| Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
2 other study(ies) available for quinazolines and carfilzomib
| Article | Year |
|---|---|
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mutation; Oligopeptides; Poly(ADP-ribose) Polymerases; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2016 |
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Stromal Cells | 2019 |